The Scilligence Weekly Issue No. 12
This week’s roundup of latest advancements in research, new local job postings, and something fun!
News
With the world population aging, more and more people are becoming non-responsive to the hepatitis B vaccine. A third generation hepatitis B vaccine may provide more opportunities for the immune system to respond to antibodies in elderly people.
Read More
Cambridge-based Goldfinch Bio is working on new developments in the treatment of kidney disease. Many drugs treat the symptoms of the disease but not the cause. Goldfinch is uncovering evidence that genetics may have a role in kidney disease in adults and children.
Read More
Valneva, the only vaccine candidate to go to clinical testing for the treatment of Lyme disease, has been approved to test with humans. The vaccine had success in protection against Borrelia bacteria in preclinical studies.
Read More
Vaccine against opioid drugs may be the response to the opioid epidemic.
Read More
Geneticists and anti-aging researchers have a theory that epigenetic reprogramming may be the key to reverse aging. New studies show that rejuvenating cells can treat age-related diseases.
Read More
Scientists study the kissing bug with hopes to bring awareness of Chagas disease. The disease, prevalent in Latin America, only rarely occurs in the US (or so we think…).
Read More
Jobs
Bioinformatic Analyst – GenePeeks, Cambridge, MA
Job Site
Scientist, Discovery – Momenta Pharmaceuticals – Cambridge, MA
Job Site
Scientist, Exosome Biology – Codiak BioSciences, Cambridge, MA
Job Site